Structural comparisons of class I phosphoinositide 3-kinases

Mario L Amzel, Chuan Hsiang Huang, Diana Mandelker, Christoph Lengauer, Sandra B Gabelli, Bert Vogelstein

Research output: Contribution to journalArticle

Abstract

Class I phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate cell growth. One of these kinases, PI3Kα, is frequently mutated in diverse tumour types. The recently determined structure of PI3Kα reveals features that distinguish this enzyme from related lipid kinases. In addition, wild-type PI3Kγ differs from PI3Kα by a substitution identical to a PI3Kα oncogenic mutant (His1047Arg) that might explain the differences in the enzymatic activities of the normal and mutant PI3Kα. Comparison of the PI3K structures also identified structural features that could potentially be exploited for the design of isoform-specific inhibitors.

Original languageEnglish (US)
Pages (from-to)665-669
Number of pages5
JournalNature Reviews Cancer
Volume8
Issue number9
DOIs
StatePublished - Sep 2008

Fingerprint

1-Phosphatidylinositol 4-Kinase
Phosphotransferases
Lipids
Protein Isoforms
Enzymes
Growth

ASJC Scopus subject areas

  • Cancer Research

Cite this

Structural comparisons of class I phosphoinositide 3-kinases. / Amzel, Mario L; Huang, Chuan Hsiang; Mandelker, Diana; Lengauer, Christoph; Gabelli, Sandra B; Vogelstein, Bert.

In: Nature Reviews Cancer, Vol. 8, No. 9, 09.2008, p. 665-669.

Research output: Contribution to journalArticle

@article{41fb3d75b26c4ba5bfd357af38d65b8b,
title = "Structural comparisons of class I phosphoinositide 3-kinases",
abstract = "Class I phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate cell growth. One of these kinases, PI3Kα, is frequently mutated in diverse tumour types. The recently determined structure of PI3Kα reveals features that distinguish this enzyme from related lipid kinases. In addition, wild-type PI3Kγ differs from PI3Kα by a substitution identical to a PI3Kα oncogenic mutant (His1047Arg) that might explain the differences in the enzymatic activities of the normal and mutant PI3Kα. Comparison of the PI3K structures also identified structural features that could potentially be exploited for the design of isoform-specific inhibitors.",
author = "Amzel, {Mario L} and Huang, {Chuan Hsiang} and Diana Mandelker and Christoph Lengauer and Gabelli, {Sandra B} and Bert Vogelstein",
year = "2008",
month = "9",
doi = "10.1038/nrc2443",
language = "English (US)",
volume = "8",
pages = "665--669",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Structural comparisons of class I phosphoinositide 3-kinases

AU - Amzel, Mario L

AU - Huang, Chuan Hsiang

AU - Mandelker, Diana

AU - Lengauer, Christoph

AU - Gabelli, Sandra B

AU - Vogelstein, Bert

PY - 2008/9

Y1 - 2008/9

N2 - Class I phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate cell growth. One of these kinases, PI3Kα, is frequently mutated in diverse tumour types. The recently determined structure of PI3Kα reveals features that distinguish this enzyme from related lipid kinases. In addition, wild-type PI3Kγ differs from PI3Kα by a substitution identical to a PI3Kα oncogenic mutant (His1047Arg) that might explain the differences in the enzymatic activities of the normal and mutant PI3Kα. Comparison of the PI3K structures also identified structural features that could potentially be exploited for the design of isoform-specific inhibitors.

AB - Class I phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate cell growth. One of these kinases, PI3Kα, is frequently mutated in diverse tumour types. The recently determined structure of PI3Kα reveals features that distinguish this enzyme from related lipid kinases. In addition, wild-type PI3Kγ differs from PI3Kα by a substitution identical to a PI3Kα oncogenic mutant (His1047Arg) that might explain the differences in the enzymatic activities of the normal and mutant PI3Kα. Comparison of the PI3K structures also identified structural features that could potentially be exploited for the design of isoform-specific inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=50149110036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50149110036&partnerID=8YFLogxK

U2 - 10.1038/nrc2443

DO - 10.1038/nrc2443

M3 - Article

VL - 8

SP - 665

EP - 669

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 9

ER -